General Background and Information
The Minnesota Partnership for Biotechnology and Medical Genomics is a unique collaborative venture among the Mayo Clinic, University of Minnesota, and State of Minnesota. The Partnership seeks to position Minnesota as a world leader in biotechnology and medical genomics applications that will result in important new medical discoveries, thereby improving health care for patients and supporting the development of new business and jobs in Minnesota.
In the wake of substantial breakthroughs in biological understandings and new technology, exemplified by the mapping and sequencing of the human genome, the potential for new scientific discoveries is momentous. Mayo and the University have already invested heavily in attracting important scientific talent and developing the infrastructure to support a competitive research effort. They are prepared to continue supporting this investment through a joint collaboration. However, neither Mayo nor the University can do it alone. Government investment provides the necessary leverage. The State's investment jump-starts the collaboration between the two institutions to find the areas of synergy and begin the process of translating the new knowledge into products, devices and therapeutics that also create new jobs and businesses. The State also has additional tools to facilitate this economic opportunity.
Mayo and the University recognize the potential synergy between the parties with respect to biotechnology and medical genomics research and are committed to engaging in expanded research collaborations. Researchers from both institutions have participated in discussions to develop proposed research plans. These proposals will be reviewed by panels of scientific experts to determine which projects to fund under the Partnership.
Copyright 2003-2009 Mayo Foundation for Medical Education and Research and Regents
of the University of Minnesota. All Rights Reserved.
Comments: 0